Celldex Therapeutics, Inc. (CLDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celldex Therapeutics, Inc. on April 2, 2026, covering events occurring on April 1, 2026. The Company, a Delaware corporation listed on the Nasdaq Capital Market, announced the entry into a material definitive agreement for a public equity offering.
Key Financial Metrics and Transaction Details
- Offering Size: 10,345,000 shares of Common Stock.
- Offering Price: $29.00 per share.
- Expected Net Proceeds: Approximately $282 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to 1,551,750 additional shares.
- Expected Closing Date: On or about April 6, 2026.
- Underwriters: Leerink Partners LLC and TD Securities (USA) LLC.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. Those figures are referenced as being available in the Company's Form 10-K filed on February 25, 2026.
Material Changes and Outlook
The primary material change is the anticipated increase in cash liquidity upon the closing of the Offering. The Company has issued press releases regarding the launch and pricing of the Offering. Management commentary is limited to the execution of the transaction and the expectation of closing subject to customary conditions.
Risks and Contingencies
- Closing Risk: The Offering is subject to customary closing conditions; there is no guarantee the transaction will close on a timely basis or at all.
- Forward-Looking Statements: Risks include the uncertainty of the anticipated closing date and the potential exercise of the underwriters' option.
- Legal Opinions: The legality of the issuance is supported by an opinion from Lowenstein Sandler LLP.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received in the subsequent Form 8-K or press release.
- Confirm whether the underwriters exercised the 30-day option to purchase additional shares.
- Review the Company's Form 10-K (filed February 25, 2026) for current liquidity status and cash burn rate to assess the impact of the $282 million proceeds.
- Check the Prospectus Supplement (File No. 333-275300) for specific details on the use of proceeds and risk factors.